These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 10964582)

  • 1. Each administration of cyclosporin A enhances skin microvascular reactivity in renal transplant recipients.
    Asberg A; Berg KJ; Hartmann A
    Microvasc Res; 2000 Sep; 60(2):81-90. PubMed ID: 10964582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endothelium-dependent vasodilation of the skin microcirculation in heart transplant recipients.
    Andreassen AK; Gullestad L; Holm T; Simonsen S; Kvernebo K
    Clin Transplant; 1998 Aug; 12(4):324-32. PubMed ID: 9686327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three-years experience with Neoral C2 monitoring adjusted to a target range of 500-600 ng/ml in long-term renal transplant recipients receiving dual immunosuppressive therapy.
    Carstens J
    Scand J Urol Nephrol; 2008; 42(3):286-92. PubMed ID: 18432535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safe conversion to cicloral, a generic cylosporine, in both stable and de novo renal transplant recipients.
    Kahn D; Muller E; Pascoe M
    Saudi J Kidney Dis Transpl; 2010 May; 21(3):426-32. PubMed ID: 20427863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclosporine reduction in the presence of everolimus: 3-month data from a Canadian pilot study of maintenance cardiac allograft recipients.
    Ross H; Pflugfelder P; Haddad H; Cantarovich M; White M; Ignaszewski A; Howlett J; Vaillancourt M; Dorent R; Burton JR;
    J Heart Lung Transplant; 2008 Feb; 27(2):197-202. PubMed ID: 18267227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single daily dose administration of cyclosporine in renal transplant recipients.
    Halim MA; Said T; Al-Otaibi T; Eleawa S; Al-Maged H; Gawish AE; Nair P; Al-Muzairai I; Nampoory MR; Al-Mousawi M
    Transplant Proc; 2007 May; 39(4):1225-7. PubMed ID: 17524939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
    Krämer BK; Montagnino G; Del Castillo D; Margreiter R; Sperschneider H; Olbricht CJ; Krüger B; Ortuño J; Köhler H; Kunzendorf U; Stummvoll HK; Tabernero JM; Mühlbacher F; Rivero M; Arias M;
    Nephrol Dial Transplant; 2005 May; 20(5):968-73. PubMed ID: 15741208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis.
    Bemelman FJ; de Maar EF; Press RR; van Kan HJ; ten Berge IJ; Homan van der Heide JJ; de Fijter HW
    Transplantation; 2009 Aug; 88(3):421-8. PubMed ID: 19667948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C2 monitoring in maintenance renal transplant recipients: is it worthwhile?
    Midtvedt K; Fauchald P; Bergan S; Høieggen A; Hallan S; Svarstad E; Bergrem H; Eriksen BO; Pfeffer PF; Dalen I; Leivestad T
    Transplantation; 2003 Oct; 76(8):1236-8. PubMed ID: 14578761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Better microvascular function on long-term treatment with lisinopril than with nifedipine in renal transplant recipients.
    Asberg A; Midtvedt K; Vassbotn T; Hartmann A
    Nephrol Dial Transplant; 2001 Jul; 16(7):1465-70. PubMed ID: 11427642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and pharmacodynamics in renal transplant recipients under treatment with cyclosporine and Myfortic.
    Brunet M; Crespo M; Millán O; Serón D; Torregrosa V; Jiménez O; Moreso F; Martorell J; Grinyo JM; Oppenheimer F
    Transplant Proc; 2007 Sep; 39(7):2160-2. PubMed ID: 17889124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of cyclosporin A on DNA repair and cancer incidence in kidney transplant recipients.
    Herman M; Weinstein T; Korzets A; Chagnac A; Ori Y; Zevin D; Malachi T; Gafter U
    J Lab Clin Med; 2001 Jan; 137(1):14-20. PubMed ID: 11150019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exercise capacity in heart transplant recipients: relation to impaired endothelium-dependent vasodilation of the peripheral microcirculation.
    Andreassen AK; Kvernebo K; Jørgensen B; Simonsen S; Kjekshus J; Gullestad L
    Am Heart J; 1998 Aug; 136(2):320-8. PubMed ID: 9704697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term results of a prospective randomized study comparing two immunosuppressive regimens, one with and one without CsA, in low-risk renal transplant recipients.
    Grimbert P; Baron C; Fruchaud G; Hemery F; Desvaux D; Buisson C; Chopin D; Dahmane D; Remy P; Pastural M; Abbou C; Weil B; Lang P
    Transpl Int; 2002 Nov; 15(11):550-5. PubMed ID: 12461659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
    Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Declining intracellular T-lymphocyte concentration of cyclosporine a precedes acute rejection in kidney transplant recipients.
    Falck P; Asberg A; Guldseth H; Bremer S; Akhlaghi F; Reubsaet JL; Pfeffer P; Hartmann A; Midtvedt K
    Transplantation; 2008 Jan; 85(2):179-84. PubMed ID: 18212621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-administration of diltiazem and cyclosporine for kidney transplant recipients: a four year follow-up study.
    Ingsathit A; Sumethkul V; Chalermsanyakorn P; Jirasiritham S
    J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S235-41. PubMed ID: 17044477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Limitations of cyclosporine C2 monitoring in pediatric heart transplant recipients.
    Hmiel SP; Canter C; Shepherd R; Lassa-Claxton S; Nadler M
    Pediatr Transplant; 2007 Aug; 11(5):524-9. PubMed ID: 17631021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients.
    Baboolal K
    Transplantation; 2003 Apr; 75(8):1404-8. PubMed ID: 12717239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.